SMTL ID : 8x2o.1

RIPK2 in complex with K252

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.26 Å

Oligo State

homo-dimer

Ligands

2 x 6IL: ~{N}-[(1~{R})-4-[4-[(6-fluoranyl-1,3-benzothiazol-5-yl)amino]thieno[2,3-d]pyrimidin-6-yl]cyclohex-3-en-1-yl]cyclopropanecarboxamide(Non-covalent)

6IL.1: 20 residues within 4Å: Chain A: L.24, S.25, V.32, A.45, V.46, K.47, E.66, L.70, L.79, I.93, T.95, E.96, Y.97, M.98, G.101, E.105, L.153, A.163, D.164, F.165 14 PLIP interactions: 14 interactions with chain A Hydrophobic interactions: A:V.32, A:K.47, A:L.79, A:T.95, A:L.153, A:A.163 Hydrogen bonds: A:K.47, A:E.66, A:T.95, A:M.98, A:E.105, A:D.164 Water bridges: A:E.105 pi-Cation interactions: A:K.47 6IL.2: 20 residues within 4Å: Chain B: L.24, S.25, V.32, A.45, V.46, K.47, E.66, L.70, L.79, I.93, T.95, E.96, Y.97, M.98, G.101, E.105, L.153, A.163, D.164, F.165 11 PLIP interactions: 11 interactions with chain B Hydrophobic interactions: B:L.24, B:V.32, B:K.47, B:T.95, B:E.105, B:L.153, B:A.163 Hydrogen bonds: B:M.98, B:E.105, B:D.164 pi-Cation interactions: B:K.47

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Chen, Y. et al., CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury. Acta Pharm Sin B (2025)

Release Date

2024-11-13

Peptides

Receptor-interacting serine/threonine-protein kinase 2: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Receptor-interacting serine/threonine-protein kinase 2